Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA
Recruiting · NCT04197414 · Observational (researchers observe without assigning treatment) · Lead sponsor: Yonsei University
View the official record on ClinicalTrials.gov →What this trial is about
Urological malignancies such as prostate cancer and renal cell cancer in Korean population have been increased due to the aged population and the westernized lifestyles. With the advancement of sequencing technologies, use of genetic mutation profiles in cancer detection and progression has been increased. However, use of circulating tumor DNA in urological malignances have been limited and few studies have been reported. Therefore, we tried to evaluate the usefulness of circulating tumor DNA in detection and monitoring of urological malignancies in Korean population. This study aims to use circulating tumor DNA in plasma and urine for the diagnosis, disease progression monitoring and therapeutic response evaluation. This study plan includes building big databases for circulating tumor DNA of urological malignancies in Korean population and to develop optimized circulating tumor DNA platform.
Who can take part
Inclusion criteria
- 1\. Patients diagnosed as urological malignances (prostate cancer, renal cell cancer, bladder cancer, and ureter cancer)
- 2\. Patients who have undergone surgeries due to urological malignancies in Severance Hospital, Sinchon from 2019.12 and 2029.11
- 3\. Those who agree to give permission to use their human source information - 4. Those who agree with this study
Exclusion criteria
- 1\. Those who do not agree with this study
- 2\. Vulnerable participants who are likely to be vulnerable to coercion or undue influence or lack decision-making
Where it is running
1 location listed.
- Department of Urology, Urological Science Institute, Yonsei University, Colleage of Medicine - Seoul, South Korea